Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

Summary

Multi-site, randomized controlled trial to determine whether patients who report NO symptomatic benefit with their maintenance hand-held inhaler(s), benefit upon switching to nebulized therapy using comparable classes of medications.

Eligibility

Inclusion Criteria:

* \> 10 pack-years smoking cigarettes
* Diagnosis of COPD based on GOLD Criteria
* Patients are clinically stable for the past 4 weeks
* Prior Pulmonary function tests showing FEV1 \< 50% predicted (either 30 minutes post albuterol or within 2-4 hours after using their maintenance long-acting inhaler) within the past 12 months.
* Currently using a single pMDI or a single DPI with either LABA/LAMA or LABA/LAMA/ICS therapy for at least one month.

Exclusion Criteria:

* Current diagnosis of dementia or known cognitive impairment.
* Current impairment in manual dexterity (i.e., severe rheumatoid arthritis, severe tremor, etc)
* Exacerbation of COPD within the last 2 months
* Current diagnosis of other respiratory disease including asthma, treatment with a LABA/LAMA slow mist inhaler or treatment with SABA/SAMA nebulizer medications 3-4 times per day as maintenance therapy
* Current use of daily Prednisone as treatment for COPD

Conditions3

Locations2 sites

Find trials near these locations

Browse More Trials